Maud Brandely, Chief Medical Officer of Transgene, said: “We are pleased to be continuing the development of our internally discovered and developed immunotherapy TG1050. The Phase 1/1b trial is progressing well with no severe adverse events observed. We are now moving ahead with the enrollment of the multiple dose cohorts of this study. Chronic hepatitis B is a major unmet medical need, and with TG1050, we are looking to provide a much more-effective treatment that is urgently needed for this viral liver disease, which can lead to cirrhosis and liver cancer.”
This first-in-man trial is an international, randomized, multi-center, double-blind, placebo-controlled study evaluating TG1050 in patients who are currently being treated for chronic HBV infection with standard-of-care antiviral therapy.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||3.09 (c)||-2.52%||66 350|